Novartis Announced That The European Commission (Ec) Approved Tabrecta (Capmatinib) As A Monotherapy For The Treatment Of Adults With Advanced Non-Small Cell Lung Cancer (Nsclc) Harbouring Alterations Leading To Mesenchymal-Epithelial-Transition Factor Gene (Met) Exon 14 (Metex14) Skipping Who Require Systemic Therapy Following Prior Treatment With Immunotherapy And/Or Platinum-Based Chemotherapy.The Approval Follows A Positive Opinion Issued In April By The Committee For Medicinal Products For Human Use (Chmp) Of The European Medicines Agency (Ema) And Is Applicable To All 27 European Union Member States Plus Iceland, Norway And Liechtenstein.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!